Active, not recruitingPhase 3NCT03671148

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Studying NON RARE IN EUROPE: Psoriatic arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AbbVie
Principal Investigator
ABBVIE INC.
AbbVie
Intervention
Placebo(biological)
Enrollment
444 enrolled
Eligibility
18 years · All sexes
Timeline
20192020

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03671148 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Psoriatic arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Psoriatic arthritis

← Back to all trials